Inclusion Criteria:

- Patients over 18 years of age, of any race or sex, who have hepatocellular carcinoma
of the liver

- Patients who are able to give informed consent, will be eligible.

- Patients must have an ECOG Performance Status score of < or = 2

- Must have a life expectancy of > 3 months

- Non-pregnant with an acceptable contraception in premenopausal women

- Patients must be > 4 weeks since prior radiation or prior surgery and at least 1
month post chemotherapy

Exclusion Criteria:

- Contraindications to angiography and selective visceral catheterization

- Evidence of potential delivery of greater than 16.5 mCi (30 Gy absorbed dose) per
treatment of radiation to the lungs

- Evidence of any detectable Tc-99m MAA flow to the stomach or duodenum, after
application of established angiographic techniques to stop or mitigate such flow (ex.
placing catheter distal to gastric vessels)

- Significant extrahepatic disease representing an imminent life-threatening outcome

- Severe liver dysfunction or pulmonary insufficiency

- Active uncontrolled infection

- Significant underlying medical or psychiatric illness

- Pregnancy

- Patients will be excluded if they have pre-existing diarrhea/illness, or if they have
a co-morbid disease or condition that would preclude safe delivery of TheraSphere
treatment and place the patient at undue risk.